Shire To Present Additional Scientific Data On ADHD Treatment Portfolio At American Psychiatric Association Annual Meeting

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.

Sensory Treatment Reduces Autistic Mannerisms

Parents of children with autism are increasingly turning to sensory integration treatment to help their children deal with the disorder, and they're seeing good results. In 2007, 71 percent of parents who pursued alternatives to traditional treatment used sensory integration methods, and 91 percent found these methods helpful.

FDA Approves Strattera R For Maintenance Of ADHD In Children And Adolescents

Eli Lilly and Company (NYSE: LLY) announced that the United States Food and Drug Administration (FDA) has approved Strattera(R) (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents.

MGH Study Confirms Benefit Of Surgery For Gastroesophageal Reflux

Despite the growing availability of prescription and over-the-counter medications for gastroesophageal reflux disease (GERD), surgical treatment remains a viable alternative for patients whose symptoms persist. In the May 2008 Archives of Surgery, surgeons from Massachusetts General Hospital (MGH) report their survey of almost 200 patients who had laparoscopic antireflux surgery at the MGH over a 10-year period.

TAK-390MR Phase 3 Data Presented At Digestive Disease Week

TAP Pharmaceutical Products Inc. have reported results from three pivotal Phase 3 studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor (PPI) with an innovative dual delayed release technology, in healing patients with erosive esophagitis (EE) and in maintenance of healed EE.

Simplicity Of Working Memory Study Could Help With ADD And Other Attention Difficulties

A mind is a terrible thing to waste, but humans may have even less to work with than previously thought. University of Missouri researchers found that the average person can keep just three or four things in their "working memory" or conscious mind at one time.

Shire Investigational Nonstimulant INTUNIV Showed Significant Efficacy In Reducing ADHD Symptoms

Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, has presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).

Researcher Reports On Noninvasive Device For GERD, Obesity

A new, noninvasive gastroplasty device to treat two separate disorders gastroesophageal-reflux disease (GERD) and morbid obesity was reported by its inventor, Charles J. Filipi, M.D., professor of surgery at Creighton University School of Medicine.

New Analysis In Boys And Girls Shows The ADHD Patch, DAYTRANA TM methylphenidate Transdermal System , Offered ADHD Symptom Control For 12 Months

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA(TM) (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).

OROS R Methylphenidate In Adults With ADHD: New Insights

Although once considered to be a disorder only seen in children, Attention Deficit Hyperactivity Disorder (ADHD) is now known to be a condition associated with a wide range of functional impairments throughout the lifespan(1). In the US, the overall prevalence of ADHD in adults is estimated to range between 3.